Glenmark Pharmaceuticals enters into Strategic Development & Licensing Agreement with Celon

23 Oct 2015 Evaluate

Glenmark Pharmaceuticals Europe (Glenmark) has entered into a Strategic Development & Licensing Agreement with Celon Pharma S.A. (Celon) to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product - Fluticasone /Salmeterol dry powder Inhaler in Europe upon commercialization.

As per the terms of the agreement, the company has obtained Semi-exclusive Marketing & Distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania among others. Celon on the other hand, shall receive an upfront payment followed by certain milestone payments during various stages of the product’s development from the company including Royalties on sales. The distribution agreement was concluded for a period of 10 years, with an option of a two-year extension.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical company and ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues.

Glenmark Pharma Share Price

1540.70 -52.20 (-3.28%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.